Repligen Corp. (RGEN)
166.82
+0.40
(+0.24%)
USD |
NASDAQ |
Jan 09, 16:00
166.55
-0.27
(-0.16%)
After-Hours: 20:00
Repligen Research and Development Expense (Annual): 42.75M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Enovis Corp. | 91.30M |
| Perspective Therapeutics, Inc. | 39.33M |
| InfuSystem Holdings, Inc. | -- |
| Xtant Medical Holdings, Inc. | 2.385M |
| VolitionRX Ltd. | 13.32M |